Arvinas, Inc. (NASDAQ: ARVN) reveals that Sean Cassidy, C.P.A, Chief Financial Officer and Treasurer, will depart from the company after over a decade of dedicated service, effective February 29, 2024, to pursue new opportunities. In response, the Arvinas Board of Directors has initiated a formal search process to identify Cassidy’s permanent successor. During this interim period, Randy Teel, Ph.D., Arvinas’ Senior Vice President of Corporate and Business Development, will step in as the interim Chief Financial Officer and Treasurer.
Arvinas boasts four programs in clinical trials, focusing on investigational proteolysis-targeting chimera (PROTAC®) degraders for breast cancer, prostate cancer, and neurodegenerative diseases. With sufficient financial resources expected to sustain operations until 2027, Arvinas remains steadfast in its commitment to advancing transformative therapies.
John Houston, Ph.D., Chairperson, Chief Executive Officer, and President at Arvinas, acknowledges Cassidy’s significant contributions since 2013, praising his instrumental role in shaping Arvinas’ financial landscape and nurturing a skilled finance team amid the company’s groundbreaking advancements with its PROTAC® platform. Houston expresses gratitude for Cassidy’s leadership and friendship, wishing him success in his future endeavors.
Cassidy reflects on his tenure, expressing confidence in Arvinas’ trajectory and the potential of its PROTAC® protein degrader pipeline to address unmet medical needs. He extends well wishes to his colleagues as they continue to pursue the company’s vision of leveraging innovative technology for the benefit of patients.
Have you read?
Countries With The Highest And Lowest Average Salaries, 2023.
Best Fashion Schools In The World.
Best Business Schools In The World.
The World’s Best CEOs And C-Suite Executives, 2023.
World’s Most Influential and Innovative Companies.
World’s Best Hospitality And Hotel Management Schools.
